Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC December Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Liraglutide (Victoza®) has been accepted for restricted use for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control. It is restricted to a third line position after metformin and a sulphonylurea.

Pramipexole (Mirapexin®) in a modified release formulation has been accepted for use in the treatment of Parkinson’s disease. An economic analysis found that the once daily formulation could provide the benefit of once-daily rather than thrice-daily dosing, at an equivalent cost.

Tafluprost preservative-free eye drops (Saflutan®) have been accepted for restricted for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. The product is restricted to use in those patients with a proven sensitivity to the preservative benzalkonium chloride in currently available prostaglandin preparations.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC December Update' on Email Share 'SMC December Update' on Delicious Share 'SMC December Update' on Digg Share 'SMC December Update' on Facebook Share 'SMC December Update' on Google+ Share 'SMC December Update' on reddit Share 'SMC December Update' on StumbleUpon Share 'SMC December Update' on Twitter

atomic-wealth

No Comments to “SMC December Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,615 spam comments.

atomic-wealth
fond-illness
summer